Based on positive results in a phase III trial, Imfinzi demonstrated improvement over chemotherapy alone, the approval was granted
Sareum Holdings PLC (SAR.L) Subscription to raise £900,000
Subscription to raise £900,000 to progress proprietary TYK2/JAK1 programmes through final stages of preclinical development
Sareum Holdings PLC (SAR.L) Research Update
Sareum Notes SRA737 Combination Data to be Presented at the AACR Annual Meeting